The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease. 

The hold was lifted in under three months and led to an increase in  Rocket’s stock value by 30%. 

In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold.  

The FDA authorised the pivotal study to resume first with a recalibrated dose of 3.8 x 10¹³ GC/kg of RP-A501 in three patients, treated sequentially with a minimum four-week interval between each treatment.  

This adjusted dose aligns with the lower range of administered doses that were associated with efficacy across multiple biomarkers, echocardiographic and clinical endpoints in the Phase I study, and has been determined as most likely to confer the safety and efficacy identified in the low-dose Phase I cohorts.  

In addition, Rocket will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase I paediatric cohort.  

The revised regimen discontinues prophylactic use of a C3 complement inhibitor, while maintaining sirolimus, rituximab, and steroids. Additionally, the protocol will specify a lower threshold for administering a C5 inhibitor (eculizumab) in response to impending complement activation. 

Improving cardiac function

To date, six patients with Danon disease have been treated in the Phase II study with RP-A501. 

To support accelerated approval, the study assesses the efficacy of RP-A501 as measured by the biomarker-based co-primary endpoint consisting of improvements in LAMP2 protein expression, and reductions in left ventricular mass. 

The key secondary endpoint is change in troponin. Additional secondary endpoints include natriuretic peptides, Kansas City Cardiomyopathy Questionnaire, New York Heart Association class, event free survival to 24 months and treatment emergent safety events. 

A global natural history study is running concurrently with the Phase II pivotal trial. 

RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene (AAV9.LAMP2B) which is administered as a single intravenous (IV) infusion.  

In clinical studies, RP-A501 has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which led to improved cardiac structure and function in patients.  

RP-A501 holds FDA RMAT, Fast Track, Rare Pediatric, and Orphan Drug designations in the US along with ATMP and PRIME designations in the EU. 

Diana Turner, Senior Digital Content Editor, DDW